Bausch + Lomb | BLCO | Long at $16.02
Bausch + Lomb 
BLCO, a strong name in the eye health world, is trading within my historical simple moving average area and appears to be gaining upward momentum. I usually do not like to enter companies this earlier (more data is always better), but this company has very strong earnings and a solid track record. Earnings are forecasted to grow 57% per year and it's trading at a good value compared to its peers (price-to-book: 0.87x, price-to-sales: 1.17x). Low debt-to-equity (0.74x). Product exposure is across the globe and revenue was $4.8 billion in FY2024. Profitability has fluctuated over the years, and tariffs or other global trade issues are always a concern. Also, it's very early in this stock's history to gauge future performance. I would not exclude a call to the $14.00 area in the near-term, so there absolutely risks with this pick.
But, at $16.02,BLCO is in a personal buy zone.
Targets:
BLCO, a strong name in the eye health world, is trading within my historical simple moving average area and appears to be gaining upward momentum. I usually do not like to enter companies this earlier (more data is always better), but this company has very strong earnings and a solid track record. Earnings are forecasted to grow 57% per year and it's trading at a good value compared to its peers (price-to-book: 0.87x, price-to-sales: 1.17x). Low debt-to-equity (0.74x). Product exposure is across the globe and revenue was $4.8 billion in FY2024. Profitability has fluctuated over the years, and tariffs or other global trade issues are always a concern. Also, it's very early in this stock's history to gauge future performance. I would not exclude a call to the $14.00 area in the near-term, so there absolutely risks with this pick. But, at $16.02,
BLCO is in a personal buy zone.Targets:
- $17.50
- $20.00
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.